To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Secondary hyperparathyroi… - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Secondary hyperparathyroidism but stable bone-mineral density in patients with chronic myeloid leukemia treated with imatinib.

Journal article
Authors Sofia Jönsson
Therese Standal
Bob Olsson
Dan Mellström
Hans Wadenvik
Published in American journal of hematology
Volume 87
Issue 5
Pages 550-2
ISSN 1096-8652
Publication year 2012
Published at Institute of Medicine, Department of Internal Medicine and Clinical Nutrition
Pages 550-2
Language en
Keywords Aged, Alkaline Phosphatase, blood, Antineoplastic Agents, adverse effects, pharmacology, therapeutic use, Biological Markers, Bone Density, Calcium, blood, Collagen Type I, blood, Female, Humans, Hyperparathyroidism, Secondary, chemically induced, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, blood, complications, drug therapy, Magnesium, blood, Male, Menopause, Middle Aged, Osteocalcin, blood, Parathyroid Hormone, blood, Peptides, blood, Piperazines, adverse effects, pharmacology, therapeutic use, Protein Kinase Inhibitors, adverse effects, pharmacology, therapeutic use, Pyrimidines, adverse effects, pharmacology, therapeutic use, Smoking, blood
Subject categories Hematology


Imatinib is currently the standard treatment for chronic myeloid leukemia(CML). Previous studies have shown that imatinib affects bone metabolism in CML patients. However, these effects are not well-studied prospectively. The authors studied bone-mineral density (BMD) and bone metabolism in 17 CML patients and matched controls in 2007 and now repeated the analyses prospectively in 2011. All CML patients were in complete cytogenetic remission during this 4-year period and treated with 400 mg imatinib q.d. (n 5 15) or 600 mg imatinib q.d. (n 5 2). Mean treatment duration was 102 months (range 69–129) in 2011. The authors found that serum levels of parathyroid hormone increased significantly in the patients between 2007 and 2011, and seven out of 17 patients had secondary hyperparathyroidism in 2011. However, the mean areal and volumetric BMDs were stable in the CML patients over the 4-year-observation period. Moreover, the CML patients had significantly higher volumetric BMD in the cortical compartment when compared with controls in 2011 and 2007. Thus, despite a high incidence of secondary hyperparathyroidism,there were no signs of osteoporosis or osteomalacia in imatinib-treated CML patients as suggested earlier.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?